{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T06:09:07Z","timestamp":1788761347346,"version":"build-2803163510"},"reference-count":26,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Gynecological Endocrinology"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/09513590.2026.2722484","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T05:56:11Z","timestamp":1788760571000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["DT56a (Femarelle) effectively manages vulvovaginal atrophy in postmenopausal women"],"prefix":"10.1080","volume":"42","author":[{"given":"Margaret","family":"Nachtigall","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, NYU Interdisciplinary Program in Menopausal Medicine, New York University School of Medicine","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lila E.","family":"Nachtigall","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, NYU Interdisciplinary Program in Menopausal Medicine, New York University School of Medicine","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,6]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012369443-0\/50024-7"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0b013e3182a122c2"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0029-7844(00)00930-3"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e3181f2f01a"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2007.03.004"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2006.02.010"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2005.02.007"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0960-0760(03)00252-8"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2005.00573.x"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e31819b351e"},{"issue":"2","key":"e_1_3_5_12_1","first-page":"123","article-title":"Efficacy and safety of standard versus low-dose femarelle (DT56a) for the treatment of menopausal symptoms","volume":"31","author":"Yoles I","year":"2004","unstructured":"Yoles I , Yogev Y , Frenkel Y , et al. Efficacy and safety of standard versus low-dose femarelle (DT56a) for the treatment of menopausal symptoms. Clin Exp Obstet Gynecol. 2004;31(2):123\u2013126.","journal-title":"Clin Exp Obstet Gynecol"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.GME.0000064864.58809.77"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.3275\/8926"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2005.08.002"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03347039"},{"key":"e_1_3_5_17_1","volume-title":"Estrogen and Estrogen\/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms \u2014 Recommendations for Clinical Evaluation. Guidance for Industry.","author":"U. S. Food and Drug Administration","year":"2003","unstructured":"U. S. Food and Drug Administration , Estrogen and Estrogen\/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms \u2014 Recommendations for Clinical Evaluation. Guidance for Industry. Rockville, MD: FDA; 2003. Available from: https:\/\/www.FDA.gov\/regulatory-information\/search-FDA-guidance-documents\/estrogen-and-estrogenprogestin-drug-products-treat-vasomotor-symptoms-and-vulvar-and-vaginal-atrophy?utm_source=chatgpt.com"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e3181a48c4e"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042192-200211000-00005"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2010.08.001"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e31817b076a"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0b013e3182a122c2"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e3181c1ac01"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e318199e734"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e3181a48c4e"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2007.07.1359"},{"key":"e_1_3_5_27_1","unstructured":"Guidance for Industry Estrogen and Estrogen\/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms \u2014 Recommendations for Clinical Evaluation. 2003. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/estrogen-and-estrogenprogestin-drug-products-treat-vasomotor-symptoms-and-vulvar-and-vaginal-atrophy"}],"container-title":["Gynecological Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09513590.2026.2722484","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/09513590.2026.2722484","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09513590.2026.2722484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T05:56:13Z","timestamp":1788760573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09513590.2026.2722484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,6]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/09513590.2026.2722484"],"URL":"https:\/\/doi.org\/10.1080\/09513590.2026.2722484","relation":{},"ISSN":["0951-3590","1473-0766"],"issn-type":[{"value":"0951-3590","type":"print"},{"value":"1473-0766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=igye20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=igye20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2722484"}}